TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2026 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2026 Earnings Call Transcript May 12, 2026TriSalus Life Sciences, Inc. misses on earnings expectations.
Trisalus Life Sciences Inc. (TLSI)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,000,000 | $4,550,000 | -52% | 0.15% |
| 2. | Royce & Associates Chuck Royce | 200,060 | $910,273 | 0.01% | |
| 3. | AQR Capital Management Cliff Asness | 117,977 | $536,797 | 0% | |
| 4. | MSDC Management Marc Lisker, Glenn Fuhrman And John Phelan | 39,999 | $181,995 | 0.24% | |
| 5. | 74,826 | $56,872 | +162% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.53 | 60,000 | $151,800.00 | 147,555 | 2026-05-15 | Filing | |
| $2.50 | 200,000 | $500,000.00 | 399,698 | 2026-05-15 | Filing | |
| $2.50 | 410,000 | $1,025,000.00 | 1,240,722 | 2026-05-15 | Filing | |
| $2.59 | 39,682 | $102,776.38 | 1,065,215 | 2026-05-15 | Filing | |
| $2.43 | 7,100 | $17,253.00 | 275,757 | 2026-05-15 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.67 | 543 | $1,449.81 | 125,101 | 2026-05-15 | Filing | |
| $4.12 | 273 | $1,124.76 | 97,364 | 2026-03-16 | Filing | |
| $4.09 | 1,772 | $7,247.48 | 97,637 | 2026-03-12 | Filing | |
| $4.13 | 1,162 | $4,799.06 | 99,409 | 2026-03-11 | Filing | |
| $4.12 | 579 | $2,385.48 | 163,415 | 2026-03-16 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 6,552,491 | $29,813,834 | 1.81% | |
| 2. | 2,659,218 | $12,099,442 | 0% | |
| 3. | 1,729,385 | $7,868,702 | 0% | |
| 4. | 1,603,538 | $7,296,098 | 0.01% | |
| 5. | 1,190,067 | $5,416,203 | 0% |
News See All
8 Best Fast Growing Penny Stocks to Buy Right Now
In this article, we will discuss the 8 Best Fast Growing Penny Stocks to Buy Right Now.
Canaccord Lowers its Price Target on TriSalus Life Sciences, Inc. (TLSI) to $7 from $12 and Maintains a Buy Rating
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) is among the 11 Fastest Growing Penny Stocks to Buy Right Now.
11 Fastest Growing Penny Stocks to Buy Right Now
In this article, we will look at the 11 Fastest Growing Penny Stocks to Buy Right Now. Interest in smaller companies has been quietly building on Wall Street.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2025 Earnings Call Transcript March 5, 2026TriSalus Life Sciences, Inc. beats earnings expectations. Reported EPS is $-0.12, expectations were $-0.13.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q3 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q3 2025 Earnings Call Transcript November 13, 2025TriSalus Life Sciences, Inc. misses on earnings expectations.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q2 2025 Earnings Call Transcript August 12, 2025TriSalus Life Sciences, Inc. misses on earnings expectations.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2025 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q1 2025 Earnings Call Transcript May 15, 2025TriSalus Life Sciences, Inc. misses on earnings expectations.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q4 2024 Earnings Call Transcript March 27, 2025TriSalus Life Sciences, Inc. reports earnings inline with expectations.
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q3 2024 Earnings Call Transcript
TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Q3 2024 Earnings Call Transcript November 14, 2024TriSalus Life Sciences, Inc. misses on earnings expectations.